Charles River is a global life sciences company supporting drug development with over 70 facilities worldwide, offering various life sciences research services, including safety assessment, endotoxin detection, pathology, and molecular biology. As part of this global network, Charles River Laboratories Korea, Inc. provides essential services to the domestic life sciences and pharmaceutical industries.
Charles River's endotoxin detection solution, based on cutting-edge technology, is designed to rapidly and accurately detect even very low levels of endotoxins. Using Limulus Amoebocyte Lysate (LAL) technology, it offers a reliable endotoxin detection method that has long been a standard in life sciences research.
ABLE Labs collaborated with Technical Services Scientist Yohan Lee to conduct a Proof of Concept (PoC) for the endotoxin detection solution using the NOTABLE pipetting robot. This PoC primarily aimed to verify NOTABLE's performance in minimizing human error, ensuring reproducibility, and enhancing the accuracy and precision of pipetting.
During the approximately three-month PoC, NOTABLE was employed in various endotoxin testing tasks, such as sample dilution, endotoxin standard dilution, and dispensing of samples and reagents. During the sample preparation process, particularly when dispensing test solutions onto a 96-well plate, the NOTABLE pipetting robot significantly reduced the workload for lab personnel. It streamlined routine assays by following predetermined protocols, proving effective for handling samples that involve large volumes of stock solutions and testing quantities. Additionally, the results indicated a significant reduction in variability among experimenters by minimizing the potential for human error.
ABLE Labs plans to actively incorporate improvements identified during the PoC, such as enhancing the software UI and developing consumables tailored to specific samples, into future products and service upgrades. ABLE Labs aims to create innovative synergies by aligning its solutions with clients’ existing technologies and solutions, rather than merely providing equipment.
The ABLE Labs pipetting robot provides key elements of laboratory automation, making research and development processes more efficient and precise. Through this, clients can greatly enhance experimental reproducibility and accuracy while maximizing the utility of their existing equipment and solutions.
Collaborating with ABLE Labs will help clients improve research quality and deliver faster, more accurate results, thus strengthening their competitive position in the market. For inquiries on the adoption of the NOTABLE pipetting robot and ODM/OEM partnerships, please click the button below to contact Sales.
Charles River is a global life sciences company supporting drug development with over 70 facilities worldwide, offering various life sciences research services, including safety assessment, endotoxin detection, pathology, and molecular biology. As part of this global network, Charles River Laboratories Korea, Inc. provides essential services to the domestic life sciences and pharmaceutical industries.
Charles River's endotoxin detection solution, based on cutting-edge technology, is designed to rapidly and accurately detect even very low levels of endotoxins. Using Limulus Amoebocyte Lysate (LAL) technology, it offers a reliable endotoxin detection method that has long been a standard in life sciences research.
ABLE Labs collaborated with Technical Services Scientist Yohan Lee to conduct a Proof of Concept (PoC) for the endotoxin detection solution using the NOTABLE pipetting robot. This PoC primarily aimed to verify NOTABLE's performance in minimizing human error, ensuring reproducibility, and enhancing the accuracy and precision of pipetting.
During the approximately three-month PoC, NOTABLE was employed in various endotoxin testing tasks, such as sample dilution, endotoxin standard dilution, and dispensing of samples and reagents. During the sample preparation process, particularly when dispensing test solutions onto a 96-well plate, the NOTABLE pipetting robot significantly reduced the workload for lab personnel. It streamlined routine assays by following predetermined protocols, proving effective for handling samples that involve large volumes of stock solutions and testing quantities. Additionally, the results indicated a significant reduction in variability among experimenters by minimizing the potential for human error.
ABLE Labs plans to actively incorporate improvements identified during the PoC, such as enhancing the software UI and developing consumables tailored to specific samples, into future products and service upgrades. ABLE Labs aims to create innovative synergies by aligning its solutions with clients’ existing technologies and solutions, rather than merely providing equipment.
The ABLE Labs pipetting robot provides key elements of laboratory automation, making research and development processes more efficient and precise. Through this, clients can greatly enhance experimental reproducibility and accuracy while maximizing the utility of their existing equipment and solutions.
Collaborating with ABLE Labs will help clients improve research quality and deliver faster, more accurate results, thus strengthening their competitive position in the market. For inquiries on the adoption of the NOTABLE pipetting robot and ODM/OEM partnerships, please click the button below to contact Sales.